Hemogenyx Pharmaceuticals (LON:HEMO) Shares Down 1%

Hemogenyx Pharmaceuticals Plc (LON:HEMO) traded down 1% during trading on Monday . The company traded as low as GBX 1.58 ($0.02) and last traded at GBX 1.60 ($0.02). 3,015,726 shares traded hands during trading, a decline of 79% from the average session volume of 14,640,722 shares. The stock had previously closed at GBX 1.62 ($0.02).

Hemogenyx Pharmaceuticals Stock Down 1.0 %

The stock has a market capitalization of £21.43 million, a P/E ratio of -159.90 and a beta of 3.06. The company has a current ratio of 4.07, a quick ratio of 6.72 and a debt-to-equity ratio of 89.95. The stock’s 50 day simple moving average is GBX 2.26 and its 200 day simple moving average is GBX 2.32.

About Hemogenyx Pharmaceuticals

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants.